Trials & R&D · first seen 15h ago, updated 15h ago
Lilly sets aside up to $3.25B to tackle critical unmet need targets with InnoCare
InnoCare Pharma is the latest addition to Eli Lilly’s dealmaking spree, which includes some of the biggest acquisitions this year: up to $7 billion for Kelonia Therapeutics in April and up to $7.8 billion for Centessa Pharmaceuticals in Mar…
Summary from BioSpace - All News.